NASDAQ:ENVB Enveric Biosciences (ENVB) Stock Price, News & Analysis → Proof that the Musk/Bezos rivalry is about to hit a new level (From InvestorPlace) (Ad) Free ENVB Stock Alerts $0.92 -0.06 (-6.12%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$0.90▼$0.9950-Day Range$0.86▼$1.6652-Week Range$0.65▼$6.98Volume864,894 shsAverage Volume3.31 million shsMarket Capitalization$6.71 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Enveric Biosciences alerts: Email Address Enveric Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside987.0% Upside$10.00 Price TargetShort InterestHealthy1.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.16Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.98) to ($1.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.45 out of 5 stars 3.5 Analyst's Opinion Consensus RatingEnveric Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnveric Biosciences has received no research coverage in the past 90 days.Read more about Enveric Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.40% of the float of Enveric Biosciences has been sold short.Short Interest Ratio / Days to CoverEnveric Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enveric Biosciences has recently decreased by 62.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnveric Biosciences does not currently pay a dividend.Dividend GrowthEnveric Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENVB. Previous Next 2.1 News and Social Media Coverage News SentimentEnveric Biosciences has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Enveric Biosciences this week, compared to 1 article on an average week.Search Interest9 people have searched for ENVB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enveric Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Enveric Biosciences is held by insiders.Percentage Held by InstitutionsOnly 13.82% of the stock of Enveric Biosciences is held by institutions.Read more about Enveric Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enveric Biosciences are expected to grow in the coming year, from ($1.98) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enveric Biosciences is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enveric Biosciences is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnveric Biosciences has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Enveric Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.Discover the name and ticker of this $2 stock here >>> About Enveric Biosciences Stock (NASDAQ:ENVB)Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Read More ENVB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENVB Stock News HeadlinesMay 8, 2024 | msn.comCannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented MethodsMay 8, 2024 | businesswire.comEnveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using CannabinoidsMay 10, 2024 | InvestorPlace (Ad)You need to know these two things about AI stocks ASAP…For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.May 4, 2024 | americanbankingnews.comEnveric Biosciences (NASDAQ:ENVB) Shares Up 5.9%May 4, 2024 | americanbankingnews.comVBI Vaccines (NASDAQ:VBIV) & Enveric Biosciences (NASDAQ:ENVB) Head to Head ComparisonMarch 27, 2024 | benzinga.comEnveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future GrowthMarch 21, 2024 | uk.investing.comEnveric Biosciences Inc (ENVB)March 19, 2024 | msn.comWhy Is Anxiety/Addiction-Focused Enveric Biosciences Stock Trading Higher Tuesday?May 10, 2024 | InvestorPlace (Ad)You need to know these two things about AI stocks ASAP…For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.March 19, 2024 | msn.comEnveric gains on out-licensing deal of new chemical entities for joint disease treatmentsMarch 19, 2024 | finance.yahoo.comEnveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint DiseaseMarch 12, 2024 | finance.yahoo.comEnveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term SheetsMarch 4, 2024 | msn.comPsyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And MoreFebruary 29, 2024 | investorplace.comWhy Is Enveric Biosciences (ENVB) Stock Up 120% Today?February 29, 2024 | markets.businessinsider.comEnveric Signs Term Sheets To Pursue Out-licensing Of Three Classes Of CompoundsFebruary 29, 2024 | businesswire.comEnveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of CompoundsFebruary 26, 2024 | finance.yahoo.comCORRECTION – Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)February 23, 2024 | markets.businessinsider.comEnveric Biosciences To Sell Cannabinoid-Related Cancer Intellectual Property; Stock Up In Pre-MarketFebruary 23, 2024 | businesswire.comEnveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual PropertyFebruary 21, 2024 | msn.comEnveric Biosciences Deepens Its Mental Health-Focused Pipeline With Library of Preclinical CompoundsFebruary 21, 2024 | finance.yahoo.comEnveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health DisordersFebruary 21, 2024 | businesswire.comEnveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health DisordersFebruary 12, 2024 | msn.comPsychedelic stocks gain after FDA priority review for MDMA therapyFebruary 10, 2024 | msn.comEnveric Biosciences Granted Extension to Avoid Nasdaq DelistingJanuary 3, 2024 | finance.yahoo.comEnveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 SeriesDecember 28, 2023 | msn.comEnveric stock jumps 13% on pipeline updateDecember 28, 2023 | marketwatch.comEnveric Biosciences Shares Rise 7% After Selecting Lead Drug CandidateSee More Headlines Receive ENVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today5/10/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ENVB CUSIPN/A CIK890821 Webjaypharma.co Phone(239) 302-1707Fax732-243-9254Employees7Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+987.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($8.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-349.01% Return on Assets-187.74% Debt Debt-to-Equity RatioN/A Current Ratio1.53 Quick Ratio1.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book1.30Miscellaneous Outstanding Shares7,290,000Free Float7,206,000Market Cap$6.71 million OptionableNot Optionable Beta0.82 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Joseph Edward Tucker Ph.D. (Age 55)CEO & Director Comp: $450.79kMr. Kevin M. Coveney CPA (Age 60)Chief Financial Officer Comp: $385.62kDr. Peter J. Facchini Ph.D. (Age 60)Chief Innovation Officer Comp: $233.27kKey CompetitorsHillstream BioPharmaNASDAQ:HILSKinetaNASDAQ:KAAinosNASDAQ:AIMDLixte BiotechnologyNASDAQ:LIXTYumanity TherapeuticsNASDAQ:YMTXView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 273,000 shares on 2/13/2024Ownership: 9.964%Frank PasqualoneBought 1,000 shares on 9/15/2023Total: $2,140.00 ($2.14/share)View All Insider TransactionsView All Institutional Transactions ENVB Stock Analysis - Frequently Asked Questions Should I buy or sell Enveric Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enveric Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENVB shares. View ENVB analyst ratings or view top-rated stocks. What is Enveric Biosciences' stock price target for 2024? 1 Wall Street analysts have issued twelve-month target prices for Enveric Biosciences' stock. Their ENVB share price targets range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 987.0% from the stock's current price. View analysts price targets for ENVB or view top-rated stocks among Wall Street analysts. How have ENVB shares performed in 2024? Enveric Biosciences' stock was trading at $1.30 at the beginning of 2024. Since then, ENVB stock has decreased by 29.2% and is now trading at $0.92. View the best growth stocks for 2024 here. Are investors shorting Enveric Biosciences? Enveric Biosciences saw a decline in short interest in April. As of April 15th, there was short interest totaling 95,600 shares, a decline of 62.5% from the March 31st total of 254,900 shares. Based on an average trading volume of 4,250,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 1.4% of the company's stock are sold short. View Enveric Biosciences' Short Interest. When is Enveric Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ENVB earnings forecast. How were Enveric Biosciences' earnings last quarter? Enveric Biosciences, Inc. (NASDAQ:ENVB) announced its earnings results on Monday, March, 25th. The company reported ($1.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.55) by $0.09. What ETF holds Enveric Biosciences' stock? AdvisorShares Psychedelics ETF holds 278,833 shares of ENVB stock, representing 3.78% of its portfolio. When did Enveric Biosciences' stock split? Enveric Biosciences shares reverse split on Friday, July 15th 2022. The 1-50 reverse split was announced on Friday, July 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Enveric Biosciences? Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENVB) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaProof that the Musk/Bezos rivalry is about to hit a new levelInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap Profits[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
